Pure Global AI
jRCT2031220146Recruitment Completed

Untitled Trial

A 52 week study comparing the efficacy and safety of once weekly IcoSema and once weekly insulin icodec, both treatment arms with or without oral anti diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily basal insulin. (NN1535 4591,COMBINE1) (COMBINE 1)
Novo Nordisk Pharma Ltd.Japan Registry Clinical Trial
VerifiedJapan Registry Clinical Trial
Study focus
Disease/Condition
type 2 diabetes
Study type
Interventional
Sponsor & location
Primary sponsor
Novo Nordisk Pharma Ltd.
Location
Australia;Belgium;Bulgaria;China;Croatia;Finland;India;Italy;South Korea;Mexico;Norway;Poland;Portug
Timeline & enrollment
Phase
N/A
Start date
N/A
End date
N/A
ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
Japan Registry Clinical Trial
Trial ID
jRCT2031220146
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for jRCT2031220146 through Pure Global AI's free database. This phase not specified trial is sponsored by Novo Nordisk Pharma Ltd. and is currently Recruitment Completed. The study focuses on type 2 diabetes.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.